A 28-Day, Randomized, Controlled, Single-Blind, Phase 2 Study in Treatment-Resistant Major Depressive Disorder (TRD) Patients Receiving Intranasal Esketamine Comparing Addition of Almond Therapy TM with Treatment-as-Usual (TAU)

INTRODUCTION: Treatment Resistant Depression (TRD) occurs in up to 30% of patients with Major Depressive Disorder (MDD). New treatments are clearly needed and there is a burgeoning interest in novel agents including ketamine. While ketamine in various formulations has been demonstrated to have a rob...

Descripción completa

Detalles Bibliográficos
Autores principales: Chue, P., Silverstone, P., Hillier, T., Rizvi, S., Phillips, S., Langkaas, L.-A., Davidson, K., Brown, M., Chue, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434349/
http://dx.doi.org/10.1192/j.eurpsy.2023.903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434349/
http://dx.doi.org/10.1192/j.eurpsy.2023.903

Ejemplares similares